Cell cycle kinases as therapeutic targets for cancer

By S. Lapenna, Antonio Giordano. Nature reviews. Drug discovery, 2009

922 citations recorded by the source corpus.

Subfields: Cell Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/fae1a1be9c1f0723b0c8e57d03e75487a4428798

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. Yves Pommier
2. Christophe H. Marchand
3. Hongliang Zhang
4. E. Musgrove
5. Elisabetta Leo

In Oncology

1. Yves Pommier
2. Christophe H. Marchand
3. Hongliang Zhang
4. Elisabetta Leo
5. E. Musgrove
6. Mark J. O'Connor

In Pulmonary and Respiratory Medicine

1. Yves Pommier
2. Christophe H. Marchand
3. Hongliang Zhang
4. E. Musgrove
5. Elisabetta Leo

Citations in the corpus

• A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets (2012, background): “In addition, our study also highlights interesting therapeutic opportunitiesdfor example, the cyclin-dependent kinase CDK6 was frequently amplified in our series, and small molecule-targeted inhibitors of CDK have been developed.(52) A notable finding in this study was that GATA4, GATA6 and KLF5 are”
• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity (2011, background): “CHK2 inhibition has been proposed as a strategy to increase the therapeutic impact of DNA-damaging cancer therapies and inhibitors of CHK2 are in clinical trial”
• Radiation-induced cell death mechanisms (2010, background): “Several inhibitors are currently investigated in pre-clinical and clinical studies including aurora kinases [137, 138], PLK1 [83, 136 ], survivin [139], and kinesin family members (KIF11, KIFC1) [140, 141].”
• Cyclin D as a therapeutic target in cancer (2011, background): “Early evidence of the high incidence of aberrant cyclin expression in myriad cancer types and the sensitivity of cancer cells to acute inhibition of cyclins or CDKs, including cyclin D1, led to programmes that aimed to develop small-molecule CDK inhibitors as therapeutic”
• DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs (2010, positive): “The ongoing development of specific Chk1 and Chk2 inhibitors should provide promising combinations with Top1 inhibitors (Lapenna and Giordano, 2009; Pommier et al., 2006b).”